-

Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avadel Pharmaceuticals plc (NasdaqGM: AVDL) to Alkermes plc (NasdaqGS: ALKS). Under the terms of the proposed transaction, shareholders of Avadel will receive $18.50 per share, plus a non-transferable contingent value right entitling holders to a potential additional cash payment of $1.50 per share, contingent upon final FDA approval of LUMRYZ™ for the treatment of idiopathic hypersomnia in adults by the end of 2028. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-avdl/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Contacts

Kahn Swick & Foti, LLC
Lewis S. Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
855-768-1857
1100 Poydras St., Suite 960
New Orleans, LA 70163

Industry:

Kahn Swick & Foti, LLC

NASDAQ:AVDL
Release Versions
English

Contacts

Kahn Swick & Foti, LLC
Lewis S. Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
855-768-1857
1100 Poydras St., Suite 960
New Orleans, LA 70163

Social Media Profiles
KSF on Facebook
KSF on Instagram
KSF on LinkedIn
KSF on TikTok
KSF on YouTube
More News From Kahn Swick & Foti, LLC

Navan Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Navan, Inc. - NAVN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Navan, Inc. (“Navan” or the “Company”) (NasdaqGS: NAVN).Navan, headquartered in Palo Alto, California, provides booking and expense management software for business travelers. On or about October 31, 2025, Navan conducted its initial public offering (the “IPO” or “Offering”), selling...

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (“Sarepta” or the “Company”). Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta's most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. A...

Capital Bancorp Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Capital Bancorp, Inc. - CBNK

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Capital Bancorp, Inc. ("Capital") (NasdaqGS: CBNK) to Peoples Bancorp Inc. ("Peoples") (NasdaqGS: PEBO). Under the terms of the proposed transaction, shareholders of Capital will receive 1.11 shares of Peoples common stock for each share of Capital that they own. Upon closing of the proposed transac...
Back to Newsroom